Red blood cell supports in severe clinical conditions in sickle cell diseases

Basit Öğe Kaydı
dc.contributor.authorHelvaci, Mehmet Rami
dc.contributor.authorAtci, Nesrin
dc.contributor.authorAyyildiz, Orhan
dc.contributor.authorMuftuoglu, Orhan Ekrem
dc.contributor.authorPocock, Lesley
dc.date.accessioned2024-09-18T20:57:02Z
dc.date.available2024-09-18T20:57:02Z
dc.date.issued2016
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractBackground: Sickle cell diseases (SCDs) are accelerated atherosclerotic processes. We tried to understand whether or not there is a prolonged survival with the increased number of red blood cells (RBC) transfusion in the SCDs. Methods: As one of the significant endpoints of the SCDs, cases with chronic obstructive pulmonary disease (COPD) and without, were collected into the two groups. Results: The study included 428 patients (221 males). There were 71 patients (16.5%) with COPD. Mean age was significantly higher in the COPD group (32.8 versus 29.8 years, P=0.005). Male ratio was significantly higher in the COPD group, too (78.8% versus 46.2%, P<0.001). Smoking (35.2% versus 11.4%, P<0.001) and alcohol (7.0% versus 1.9%, P<0.01) were also higher among the COPD cases. Beside these, priapism (14.0% versus 3.0%, P<0.001), HCV RNA positivity (2.7% versus 0.5%, P<0.05), cirrhosis (8.4% versus 3.3%, P<0.05), leg ulcers (23.9% versus 12.0%, P<0.01), digital clubbing (25.3% versus 6.7%, P<0.001), coronary heart disease (23.9% versus 13.7%, P<0.05), chronic renal disease (15.4% versus 7.0%, P<0.01), stroke (16.9% versus 8.1%, P<0.01), and mean transfused RBC units in their lives (63.8 versus 33.0, P=0.003) were all higher among the COPD cases. This was probably due to the higher number of transfused RBC units; the mean age of mortality was also higher in the COPD group, significantly (38.3 versus 30.4 years, P=0.04). Conclusion: SCDs are chronic catastrophic processes on vascular endothelium terminating with accelerated atherosclerosis induced endorgan failures in early years of life. RBC supports in severe clinical conditions probably prolong survival of the patients.en_US
dc.identifier.endpage18en_US
dc.identifier.issn1839-0188
dc.identifier.issn1839-0196
dc.identifier.issue5en_US
dc.identifier.startpage11en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12483/12248
dc.identifier.volume14en_US
dc.identifier.wosWOS:000389890700004en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherMedi+World Inten_US
dc.relation.ispartofWorld Family Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSickle cell diseasesen_US
dc.subjectchronic endothelial damageen_US
dc.subjectred blood cell supporten_US
dc.titleRed blood cell supports in severe clinical conditions in sickle cell diseasesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu